Stock SplitsBy The Online Investor Staff, updated Mon., Jul. 22, 8:29 AM
|This Slide: #4 of 25|
Slide #4. Xenetic Biosciences, Inc. (NASDAQ:XBIO) — 1 for 12 Reverse Split
1 for 12
Xenetic Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, research and development of biologic drugs and oncology therapeutics. Co.'s lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progestin - resistant endometrial cancer. Co.'s second internal drug candidate is ErepoXen, or polysialylated erythropoietin (PSA-EPO), which uses Co.'s PolyXen platform technology for the treatment of anemia in chronic kidney disease patients. Co.'s drug candidate OncoHist, which has clinical proof of concept, utilizes the properties of modified human histone H1.3 for targeted cell killing.
XBIO Detailed Information Page & Split History »